150 related articles for article (PubMed ID: 38310383)
21. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
22. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections.
Gangl O; Sahora K; Kornprat P; Margreiter C; Primavesi F; Bareck E; Schindl M; Längle F; Öfner D; Mischinger HJ; Pratschke J; Gnant M; Függer R
World J Surg; 2014 Feb; 38(2):456-62. PubMed ID: 24121365
[TBL] [Abstract][Full Text] [Related]
23. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
[TBL] [Abstract][Full Text] [Related]
24. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
25. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
Hank T; Hinz U; Tarantino I; Kaiser J; Niesen W; Bergmann F; Hackert T; Büchler MW; Strobel O
Br J Surg; 2018 Aug; 105(9):1171-1181. PubMed ID: 29738626
[TBL] [Abstract][Full Text] [Related]
26. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
27. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
28. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
29. [Laparoscopic pancreaticoduodenectomy with a novel artery first and uncinate process first approach through Treitz ligament].
Gao WT; Xi CH; Tu M; Dai XL; Guo F; Chen JM; Wei JS; Lu ZP; Wu JL; Jiang KR; Miao Y
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):359-363. PubMed ID: 28464576
[No Abstract] [Full Text] [Related]
30. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
31. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.
Maeda S; Moore AM; Yohanathan L; Hata T; Truty MJ; Smoot RL; Cleary SP; Nagorney DM; Grotz TE; Park EJ; Girgis MD; Reber HA; Motoi F; Masuda T; Unno M; Kendrick ML; Donahue TR
Surgery; 2020 May; 167(5):803-811. PubMed ID: 31992444
[TBL] [Abstract][Full Text] [Related]
32. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; Yu J; Borel Rinkes IHM; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Eur J Surg Oncol; 2019 Sep; 45(9):1674-1683. PubMed ID: 31023560
[TBL] [Abstract][Full Text] [Related]
33. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
34. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.
Hartwig W; Gluth A; Hinz U; Koliogiannis D; Strobel O; Hackert T; Werner J; Büchler MW
Br J Surg; 2016 Nov; 103(12):1683-1694. PubMed ID: 27686238
[TBL] [Abstract][Full Text] [Related]
35. [Prognosis and complications of local excision for rectal cancer after neoadjuvant chemoradiotherapy].
Li YH; Qiu XY; Lin GL; Zhou JL; Xiao Y; Qiu HZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):344-351. PubMed ID: 33878824
[No Abstract] [Full Text] [Related]
36. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis.
Machairas N; Raptis DA; Velázquez PS; Sauvanet A; Rueda de Leon A; Oba A; Koerkamp BG; Lovasik B; Chan C; Yeo CJ; Bassi C; Ferrone CR; Kooby D; Moskal D; Tamburrino D; Yoon DS; Barroso E; de Santibañes E; Kauffmann EF; Vigia E; Robin F; Casciani F; Burdío F; Belfiori G; Malleo G; Lavu H; Hartog H; Hwang HK; Han HS; Marques HP; Poves I; Domínguez-Rosado I; Park JS; Lillemoe KD; Roberts K; Sulpice L; Besselink MG; Abuawwad M; Del Chiaro M; de Santibañes M; Falconi M; D'Silva M; Silva M; Hilal MA; Qadan M; Sell NM; Beghdadi N; Napoli N; Busch ORC; Mazza O; Muiesan P; Müller PC; Ravikumar R; Schulick R; Powell-Brett S; Abbas SH; Mackay TM; Stoop TF; Gallagher TK; Boggi U; van Eijck C; Clavien PA; Conlon KCP; Fusai GK
Ann Surg; 2021 Nov; 274(5):721-728. PubMed ID: 34353988
[TBL] [Abstract][Full Text] [Related]
38. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
39. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients.
Kwon J; Shin SH; Yoo D; Hong S; Lee JW; Youn WY; Hwang K; Lee SJ; Park G; Park Y; Lee W; Song KB; Lee JH; Hwang DW; Kim SC
Medicine (Baltimore); 2020 Sep; 99(37):e22115. PubMed ID: 32925757
[TBL] [Abstract][Full Text] [Related]
40. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
